Effect of Hepatic Impairment on LDK378 Pharmacokinetics
Completed · Phase 1
Conditions studied: Normal Hepatic Function, Impaired Hepatic Function
In brief
Pharmacokinetics and safety of 750 mg of LDK378 given once orally in subjects with impaired hepatic function and healthy subjects with normal hepatic function.
Key facts
- Study ID
- NCT01950481
- Run by
- Novartis Pharmaceuticals
- People needed
- 36
- Starts
- 2014-01-01
- Expected to finish
- 2016-09-01
- Last updated by the study team
- 2020-12-19
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.
Where it is running
- DaVita Clinical Research-Denver — Lakewood, Colorado, United States
- Avail. Clinical Research, LLC — DeLand, Florida, United States
- Clinical Research of Miami, INC CLDK378A2110 — Miami, Florida, United States
- Orlando Clinical Research Center — Orlando, Florida, United States
- DaVita Clinical Research — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.